Workshop: Advancing Novel Surrogate Endpoints for Rare Disease Drug Development
The Triangle Center of Excellence in Regulatory Science & Innovation (Triangle CERSI) invites you to join FDA, researchers, clinicians, and innovators for a free, one-day virtual workshop open to the public focused on emerging scientific and regulatory pathways for advancing surrogate endpoints in rare disease drug development.
This workshop is being convened in support of the Rare Disease Endpoint Advancement (RDEA) Pilot Program, established under the FDA User Fee Reauthorization Act of 2022 and the Food and Drug Omnibus Reform Act of 2022. The RDEA program is intended to support the development of efficacy endpoints for rare disease treatments by fostering dialogue among FDA, researchers, clinicians, industry, patient communities, and other stakeholders.
Triangle CERSI is partnering with the UNC School of Medicine to offer ACCME-based continuing medical education credit.
Accelerate your ideas through customer discovery and market opportunity validation!
KickStart Venture Services is recruiting community startups as well as faculty, post-doctoral fellows, graduate students, and undergraduate students with innovations and an interest in commercialization to participate in their virtual NSF I-Corps program. They will teach you the principles of customer discovery to help you better understand the market potential of your innovation!
The National Science Foundation’s Innovation Corps Program (I-Corps) was launched in 2011 and has quickly become one of the world’s largest and most successful technology commercialization accelerators. The I-Corps regional program helps researchers and aspiring innovators determine if they are solving a real-world problem with true market opportunity. NSF’s I-Corps Program not only provides funding, mentoring, and networking opportunities to help commercialize promising technologies, it is offered at NO COST to the community.
For more information about the I-Corps Program, visit KickStart Venture Services.